Kyowa Kirin to launch Phozevel for kidney disease in Japan

19 February 2024

Japanese drugmaker Kyowa Kirin (TYO: 4151) announced that Phozevel Tablets (tenapanor hydrochloride, development code: KHK7791) will be launched in Japan on February 20 for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis.

Tenapanor hydrochloride, discovered and developed by Ardelyx (Nasdaq: ARDX) in the USA, is a first-in-class phosphate absorption inhibitor. The US firm launched its own tenapanor product, under the trade name Zphozah, in October last year. At that time, analysts forecast peak revenue potential of around $750 million a year for the compound.

Kyowa Kirin entered into an exclusive license agreement with Ardelyx in November 2017 for the development and commercialization rights for cardiorenal diseases in Japan, including hyperphosphatemia. Kyowa Kirin received approval for manufacturing and marketing Phozevel Tablets in September 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK